NASDAQ:ACRXAcelRx Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding AcelRx Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.31 +0.07 (+5.65 %) (As of 08/14/2020 04:00 PM ET) Add Compare Share Today's Range$1.21Now: $1.31▼$1.3350-Day Range$1.05MA: $1.16▼$1.3852-Week Range$0.70Now: $1.31▼$2.80Volume1.28 million shsAverage Volume1.09 million shsMarket Capitalization$118.32 millionP/E RatioN/ADividend YieldN/ABeta1.74 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain. The company was formerly known as SuRx Pharmaceuticals, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.Read More Beat the Market (BTM) Rank™ 3.2 Analyst's Opinion Consensus RatingAcelRx Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, no hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.28, AcelRx Pharmaceuticals has a potential upside of 303.1% from its current price of $1.31.Amount of Analyst CoverageAcelRx Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 2.7 Community Rank Outperform VotesAcelRx Pharmaceuticals has received 447 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAcelRx Pharmaceuticals has received 387 “underperform” votes. (Add your “underperform” vote.)Community SentimentAcelRx Pharmaceuticals has received 53.60% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about AcelRx Pharmaceuticals and other stocks. Vote “Outperform” if you believe ACRX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ACRX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAcelRx Pharmaceuticals does not currently pay a dividend.Dividend GrowthAcelRx Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AcelRx Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $143,038.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 8.10% of the stock of AcelRx Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 23.11% of the stock of AcelRx Pharmaceuticals is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for AcelRx Pharmaceuticals are expected to grow in the coming year, from ($0.52) to ($0.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AcelRx Pharmaceuticals is -2.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AcelRx Pharmaceuticals is -2.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 3.2Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.90 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ACRX Previous Symbol CUSIPN/A CIK1427925 Webwww.acelrx.com Phone650-216-3500Debt Debt-to-Equity RatioN/A Current Ratio3.69 Quick Ratio3.50Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$2.29 million Price / Sales51.67 Cash FlowN/A Price / Cash FlowN/A Book Value($0.52) per share Price / Book-2.52Profitability EPS (Most Recent Fiscal Year)($0.67) Net Income$-53,240,000.00 Net Margins-1,131.00% Return on EquityN/A Return on Assets-54.47%Miscellaneous Employees61 Outstanding Shares90,324,000Market Cap$118.32 million Next Earnings Date11/4/2020 (Estimated) OptionableOptionable $1.31 +0.07 (+5.65 %) (As of 08/14/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive ACRX News and Ratings via Email Sign-up to receive the latest news and ratings for ACRX and its competitors with MarketBeat's FREE daily newsletter. AcelRx Pharmaceuticals (NASDAQ:ACRX) Frequently Asked Questions How has AcelRx Pharmaceuticals' stock price been impacted by Coronavirus (COVID-19)? AcelRx Pharmaceuticals' stock was trading at $1.22 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ACRX shares have increased by 7.4% and is now trading at $1.31. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of AcelRx Pharmaceuticals? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AcelRx Pharmaceuticals in the last year. There are currently 1 sell rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for AcelRx Pharmaceuticals. When is AcelRx Pharmaceuticals' next earnings date? AcelRx Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020. View our earnings forecast for AcelRx Pharmaceuticals. How were AcelRx Pharmaceuticals' earnings last quarter? AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) announced its quarterly earnings data on Monday, August, 10th. The specialty pharmaceutical company reported ($0.08) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.14) by $0.06. View AcelRx Pharmaceuticals' earnings history. What price target have analysts set for ACRX? 3 equities research analysts have issued 1-year price targets for AcelRx Pharmaceuticals' shares. Their forecasts range from $0.84 to $8.00. On average, they anticipate AcelRx Pharmaceuticals' stock price to reach $5.28 in the next twelve months. This suggests a possible upside of 303.1% from the stock's current price. View analysts' price targets for AcelRx Pharmaceuticals. Has AcelRx Pharmaceuticals been receiving favorable news coverage? News coverage about ACRX stock has been trending positive this week, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. AcelRx Pharmaceuticals earned a news sentiment score of 2.4 on InfoTrie's scale. They also gave media headlines about the specialty pharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the near future. View the latest news about AcelRx Pharmaceuticals. Are investors shorting AcelRx Pharmaceuticals? AcelRx Pharmaceuticals saw a increase in short interest in the month of June. As of June 30th, there was short interest totaling 11,290,000 shares, an increase of 22.6% from the June 15th total of 9,210,000 shares. Based on an average trading volume of 1,100,000 shares, the short-interest ratio is presently 10.3 days. View AcelRx Pharmaceuticals' Short Interest. Who are some of AcelRx Pharmaceuticals' key competitors? Some companies that are related to AcelRx Pharmaceuticals include Zafgen (ZFGN), Spectrum Pharmaceuticals (SPPI), Rigel Pharmaceuticals (RIGL), Organogenesis (ORGO), Ocular Therapeutix (OCUL), TherapeuticsMD (TXMD), Avid Bioservices (CDMO), BELLUS Health (BLUSF), ANI Pharmaceuticals (ANIP), 89bio (ETNB), Puma Biotechnology (PBYI), Avedro (AVDR), Albireo Pharma (ALBO), Satsuma Pharmaceuticals (STSA) and CymaBay Therapeutics (CBAY). View all competitors. What other stocks do shareholders of AcelRx Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other AcelRx Pharmaceuticals investors own include Advanced Micro Devices (AMD), Novavax (NVAX), Amarin (AMRN), Amicus Therapeutics (FOLD), Inovio Pharmaceuticals (INO), TG Therapeutics (TGTX), Cyberark Software (CYBR), Opko Health (OPK), Flexion Therapeutics (FLXN) and NVIDIA (NVDA). Who are AcelRx Pharmaceuticals' key executives? AcelRx Pharmaceuticals' management team includes the following people: Mr. Vincent J. Angotti, CEO & Director (Age 51)Dr. Pamela Pierce Palmer, Co-Founder, Chief Medical Officer & Director (Age 56)Mr. Raffi Mark Asadorian, Chief Financial Officer (Age 50)Mr. Lawrence G. Hamel, Chief Devel. Officer (Age 67)Mr. Anil N. Dasu, Chief Engineering Officer (Age 56) What is AcelRx Pharmaceuticals' stock symbol? AcelRx Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACRX." Who are AcelRx Pharmaceuticals' major shareholders? AcelRx Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Bank of New York Mellon Corp (0.31%), Goldman Sachs Group Inc. (0.08%), Lincoln Capital Corp (0.06%), UBS Group AG (0.05%), Aigen Investment Management LP (0.04%) and Edmonds Duncan Registered Investment Advisors LLC (0.03%). Company insiders that own AcelRx Pharmaceuticals stock include Adrian Adams, Badri N Dasu, Lawrence G Hamel, Mark G Edwards, Pamela P Palmer, Raffi Asadorian and Vincent J Angotti. View institutional ownership trends for AcelRx Pharmaceuticals. Which institutional investors are selling AcelRx Pharmaceuticals stock? ACRX stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., and UBS Group AG. View insider buying and selling activity for AcelRx Pharmaceuticals. Which institutional investors are buying AcelRx Pharmaceuticals stock? ACRX stock was bought by a variety of institutional investors in the last quarter, including Aigen Investment Management LP, Edmonds Duncan Registered Investment Advisors LLC, Virtu Financial LLC, Bank of New York Mellon Corp, and Lincoln Capital Corp. Company insiders that have bought AcelRx Pharmaceuticals stock in the last two years include Adrian Adams, Mark G Edwards, Pamela P Palmer, Raffi Asadorian, and Vincent J Angotti. View insider buying and selling activity for AcelRx Pharmaceuticals. How do I buy shares of AcelRx Pharmaceuticals? Shares of ACRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is AcelRx Pharmaceuticals' stock price today? One share of ACRX stock can currently be purchased for approximately $1.31. How big of a company is AcelRx Pharmaceuticals? AcelRx Pharmaceuticals has a market capitalization of $118.32 million and generates $2.29 million in revenue each year. The specialty pharmaceutical company earns $-53,240,000.00 in net income (profit) each year or ($0.67) on an earnings per share basis. AcelRx Pharmaceuticals employs 61 workers across the globe. What is AcelRx Pharmaceuticals' official website? The official website for AcelRx Pharmaceuticals is www.acelrx.com. How can I contact AcelRx Pharmaceuticals? AcelRx Pharmaceuticals' mailing address is 351 GALVESTON DRIVE, REDWOOD CITY CA, 94063. The specialty pharmaceutical company can be reached via phone at 650-216-3500 or via email at [email protected] This page was last updated on 8/15/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
